EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV ‐Positive Head and Neck Carcinoma

Kenta Saeda, Takuya Nakagawa, Atsushi Okabe iD, Kazuko Kita, Tomoya Kurokawa, Masaki Fukuyo, Hiroki Ueda iD, Motoaki Seki iD, Bahityar Rahmutulla iD, Syuji Yonekura, Toyoyuki Hanazawa, Atsushi Kaneda iD

Cancer Science · 2026-11 · 117 (11) · 3171-3185

DOI: 10.1111/cas.70482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 16.07.2026. Verfasst von Kenta Saeda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Cisplatin, DNA Methylation, Head and Neck Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Chiba University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although human papillomavirus‐positive (HPV(+)) head and neck squamous cell carcinoma (HNSCC), particularly oropharyngeal squamous cell carcinoma (OPSCC), is generally associated with favorable outcomes, a subset of HPV(+) OPSCC remains resistant to chemoradiotherapy. We previously stratified clinical OPSCC cases using DNA methylome profiling and identified a significant correlation between elevated DNA methylation levels and favorable treatment response. To elucidate the molecular basis of this correlation, we performed integrated methylome analyses of 64 HPV(+) HNSCC cases in The Cancer Genome Atlas (TCGA) and 29 HPV(+) OPSCC cases in our Chiba cohort. We identified 595 genes showing significantly higher DNA methylation in good responders in each cohort. Additionally, using HNSCC cell lines, we extracted genes that exhibited both high DNA methylation and decreased expression in cisplatin (CDDP) sensitive cells. Twelve genes were consistently hypermethylated across both clinical cohorts, among which two genes, ROBO1 and SULT4A1 , showed statistical significance and effect size. Functional validation demonstrated that ROBO1 knockdown in unmethylated HNSCC cells significantly suppressed cellular growth ( p < 0.05), and additional exposure to CDDP further synergistically reduced cellular growth ( p < 0.05). Conversely, ROBO1 overexpression conferred resistance to CDDP. CDDP resistance in unmethylated HNSCC cells led to upregulation of ROBO1 expression, suggesting an inverse relationship between ROBO1 silencing and drug resistance. Mechanistically, ROBO1 suppression increased DNA damage and apoptosis following CDDP treatment. These indicate that DNA hypermethylation of ROBO1 causally correlates with better treatment response of HPV(+) HNSCC, and its chemosensitivity might be enhanced by silencing of methylation target genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDNA MethylationHead and Neck NeoplasmsDrug Resistance, NeoplasmNerve Tissue ProteinsReceptors, ImmunologicCarcinoma, Squamous CellPapillomavirus InfectionsHumansRoundabout ProteinsCell Line, TumorGene Expression Regulation, NeoplasticSquamous Cell Carcinoma of Head and NeckAntineoplastic AgentsHuman Papillomavirus VirusesFemaleCell Proliferation

Stichwörter der Autor:innen

DNA methylationROBO1chemosensitivitycisplatin resistanceoropharyngeal cancer

Substanzen

CisplatinRoundabout ProteinsNerve Tissue ProteinsReceptors, ImmunologicAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Health and Disease Omics Center, Chiba University, Chiba, Japan.
  • Clinical Research Center, Chiba University Hospital, Chiba, Japan.

ORCID-Profile: Atsushi Okabe, Hiroki Ueda, Motoaki Seki, Bahityar Rahmutulla, Atsushi Kaneda

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Chiba University

Zitieren

APA

Saeda, K., Nakagawa, T., Okabe, A., Kita, K., Kurokawa, T., Fukuyo, M., Ueda, H., Seki, M., Rahmutulla, B., Yonekura, S., Hanazawa, T., & Kaneda, A. (2026). Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV ‐Positive Head and Neck Carcinoma. Cancer Science, 117(11), 3171-3185. https://doi.org/10.1111/cas.70482

Vancouver

Saeda K, Nakagawa T, Okabe A, Kita K, Kurokawa T, Fukuyo M, et al. Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV ‐Positive Head and Neck Carcinoma. Cancer Science. 2026;117(11):3171-3185. doi:10.1111/cas.70482

BibTeX
@article{Saeda2026,
  author = {Saeda, Kenta and Nakagawa, Takuya and Okabe, Atsushi and Kita, Kazuko and Kurokawa, Tomoya and Fukuyo, Masaki and Ueda, Hiroki and Seki, Motoaki and Rahmutulla, Bahityar and Yonekura, Syuji and Hanazawa, Toyoyuki and Kaneda, Atsushi},
  title = {Repression of ROBO1 Enhances Cisplatin Sensitivity in Hypermethylated Subtype of HPV ‐Positive Head and Neck Carcinoma},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {11},
  pages = {3171--3185},
  doi = {10.1111/cas.70482}
}
Kostenlos starten →